Tag: gut health

The clinical landscape for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is undergoing a rapid transformation, moving far beyond their initial reputation as highly effective weight-loss agents. Recent research published across several Endocrine Society journals indicates that these medications, including semaglutide and liraglutide, are demonstrating significant therapeutic benefits for a diverse array of conditions, including polycystic…

As the global medical community witnesses a surge in the adoption of anti-obesity and glucose-lowering medications, new clinical data released in late 2025 has provided a more nuanced understanding of how these therapies influence long-term cardiac health. While the pharmaceutical market has been dominated by headlines regarding the "miracle" weight-loss capabilities of glucagon-like peptide-1 receptor…

The landscape of American medical research is currently navigating a period of significant fiscal uncertainty as Congress remains deadlocked over the completion of a full-year spending bill for the 2026 fiscal year (FY 2026). This legislative inertia has left the National Institutes of Health (NIH), the world’s premier agency for biomedical and public health research,…

The Endocrine Society, the world’s oldest and largest organization devoted to hormone research and the clinical practice of endocrinology, has announced a comprehensive expansion of its support systems for basic and clinical researchers. This strategic initiative, approved unanimously by the Society’s Board of Directors, focuses on a three-pronged framework: Presenting, Publishing, and Mentorship. By increasing…

The Endocrine Society has officially ushered in the 2026 calendar year by unveiling its prestigious Laureate Award winners, a move that signals both a celebration of past achievements and a roadmap for the future of hormonal research and clinical practice. This annual tradition, often regarded as the highest honor within the field of endocrinology, recognizes…

The landscape of metabolic medicine underwent a significant transformation in January 2026 as the United States healthcare market welcomed the commercial availability of the 25 mg oral semaglutide tablet. Marketed under the brand name Wegovy, this once-daily medication represents a pivotal expansion of the glucagon-like peptide-1 (GLP-1) receptor agonist class. Following its formal approval by…

The Endocrine Society has officially unveiled the Rare Endocrine Disease (RED) Fellows Program, a comprehensive educational initiative designed to empower the next generation of endocrinologists with the specialized expertise required to manage complex and infrequent hormonal disorders. Developed in strategic partnership with the National Organization for Rare Disorders (NORD), the program arrives at a pivotal…

The landscape of modern pharmacology is currently being reshaped by the meteoric rise of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications that has transitioned from specialized glycemic control tools to a global cultural and medical phenomenon. Originally developed to manage type 2 diabetes and later found effective for short bowel syndrome, these agents—including…

The Endocrine Society has officially announced that Samuel Klein, MD, the William H. Danforth Professor of Medicine and Nutritional Science at Washington University School of Medicine in St. Louis, is the 2026 recipient of the Outstanding Clinical Investigator Laureate Award. This prestigious recognition honors a career spanning more than three decades, during which Dr. Klein…

The pharmaceutical landscape has been fundamentally reshaped over the last several years by the rise of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of drugs that has transitioned from a specialized treatment for type 2 diabetes to a global cultural and medical phenomenon. Known colloquially through brand names such as Ozempic, Wegovy, and Mounjaro, these…